journal cover

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The Lancet Oncology

Apr 5, 2017

James L GulleyKaren Kelly

Abstract

Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this ...read more

Mentioned in this Paper

Biological Markers
Study
Monoclonal Antibodies
Platinum Compounds, Inorganic
EGFR
Radiation Pneumonitis
Chronic Airflow Obstruction
Neoplasm Recurrence, Local
Antineoplastic Agents
Clinical Study by Phase
11
1
2
179
1
Paper Details
References
  • References
  • Citations40
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations40
1234

Similar Papers Found In These Feeds

American Thoracic Society: Allergy, Immunology & Inflammation

This feed has been developed in conjunction with the American Thoracic Society for the benefit of its Allergy, Immunology, and Inflammation Assembly. It highlights new and impactful papers on allergy, asthma, genetics, and the pathogenesis of lung diseases.

American Thoracic Society: Clinical Problems

This feed has been developed in conjunction with the American Thoracic Society for the benefit of its Clinical Problems Assembly. It highlights new and impactful papers on clinical therapeutics, diagnoses, and practices pertaining to respiratory disease.

Liver Safety Biomarkers

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on liver safety biomarkers.

Chromosomal Translocation

Chromosomal Translocation occur when regions on two chromosomes breaks and swaps places or when a region is attached to another chromosome. Discover the latest research on Chromosomal Translocation here.

Drug-Induced Diseases

Drug-induced diseases (DID) also called as iatrogenic diseases. Most of these DIDs are largely preventable, if strict vigilance and proper periodic clinical and diagnostic monitoring are undertaken

X-Linked Combined Immunodeficiency Diseases

X-linked severe combined immunodeficiency is caused by mutations in the common cytokine-receptor gamma chain, resulting in disruption of development of T lymphocytes and natural-killer cells. Here is the latest research.


Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (copd) is a progressive respiratory disease associated with increasing morbidity and mortality worldwide.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

EGFR In Non-Small Cell Lung Carcinoma

Around 10-35% of non-small cell lung carcinomas have drug-sensitizing mutations in the epidermal growth factor receptor (EGFR) gene. In these cases, tyrosine kinase inhibitor therapy is recommended. Find the latest research on EGFR and non-small cell lung carcinoma here.

Copd Exacerbations

Lung Squamous Cell Carcinoma

Lung squamous cell carcinomas represent 30% of all lung cancers. This feed focuses on genetic and environmental factors that affect this cancer, as well as current therapeutic strategies. Here is the latest research.

Merkel cell carcinoma

Merkel Cell Carcinoma is a rare skin cancer characterized by red or flesh-like nodules. Increased exposure to sunlight and Merkel cell polyomavirus infection may increase risk of developing this disease. Discover the latest research on Merkel Cell Carcinoma here.

© 2020 Meta ULC. All rights reserved

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The Lancet Oncology

Apr 5, 2017

James L GulleyKaren Kelly

PMID: 28373005

DOI: 10.1016/s1470-2045(17)30240-1

Abstract

Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this ...read more

Mentioned in this Paper

Biological Markers
Study
Monoclonal Antibodies
Platinum Compounds, Inorganic
EGFR
Radiation Pneumonitis
Chronic Airflow Obstruction
Neoplasm Recurrence, Local
Antineoplastic Agents
Clinical Study by Phase
11
1
2
179
1

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations40
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations40
1234
/papers/avelumab-for-patients-with-previously-treated/28373005